Author's response to reviews

Title: Stereotactive Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach.

Authors:

Tiziana Comito (tiziana.comito@humanitas.it)
Luca Cozzi (lucozzi@iosi.ch)
Elena Clerici (elena.clerici@humanitas.it)
Maria C Campisi (maria.campisi@humanitas.it)
Rocco LE Liardo (rocco.liardo@humanitas.it)
Piera Navarria (piera.navarria@humanitas.it)
Annamaria Ascolese (annamaria.ascolese@humanitas.it)
Angelo Tozzi (angelo.tozzi@humanitas.it)
Cristina Iftode (cristina.iftode@humanitas.it)
Fiorenza De Rose (fiorenza.derose@humanitas.it)
Elisa Villa (elisa.villa@humanitas.it)
Nicola Personeni (nicola.personeni@humanitas.it)
Lorenza Rimassa (lorenza.rimassa@humanitas.it)
Armando Santoro (armando.santoro@humanitas.it)
Pietro Mancosu (pietro.mancosu@humanitas.it)
Stefano Tomatis (stefano.tomatis@humanitas.it)
Antonella Fogliata (antonella.fogliata@humanitas.it)
Marta Scorsetti (marta.scorsetti@humanitas.it)

Version: 8 Date: 17 August 2014

Author's response to reviews: see over
Dear Editor,

We have received the request of the trial registration number for the study.

We have clarified that the SABR treatment was part of the standard of care for the patients respecting the criteria specified and that the treatment was prescribed by the radiation oncologist. We have also removed the “investigator led” words as suggested.

Sincerely,

I. Cozzi for all authors.